Nine-valent, or nine-valent human papillomavirus vaccine, is not usually available over the age of 26. Nine-valent human papillomavirus vaccine is usually used to prevent related diseases, such as cervical intraepithelial neoplasia and adenocarcinoma in situ of the cervix, caused by the HPV types contained in this product, and is suitable for women between the ages of 16 and 26. Because of the age range specified in the vaccine’s package insert, women over 26 years of age are generally not vaccinated. Women over 26 years of age can receive the quadrivalent HPV vaccine, which can prevent cervical cancer, cervical intraepithelial neoplasia caused by high-risk HPV types 16/18, and two other viruses that may cause warts. It is recommended to consult with a professional healthcare provider to choose the right vaccine for your situation.